Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed.
Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently treated with metformin:
The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients treated with metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustment made as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the same as the current doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter.
No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Improvement of glycemic control in type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist patients with type 2 diabetes who are taking linagliptin and metformin together in controlling their blood sugar. It is effective in improving blood sugar management while combining dietary control and exercise therapy. It helps maintain stable blood sugar levels.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed.
Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently treated with metformin:
The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients treated with metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustment made as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the same as the current doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter.
No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This medication helps control blood sugar levels. However, it can rarely cause a serious condition called lactic acidosis, which can be very dangerous, so caution is advised.
It should not be used by individuals allergic to its components, or those with type 1 diabetes, severe kidney impairment, or severe liver dysfunction. It should also be avoided in the case of acute illnesses that can affect kidney function such as dehydration, severe infections, or acute myocardial infarction.
Due to the risk of hypoglycemia, blood sugar levels should be monitored frequently, especially when used together with other hypoglycemic agents like insulin or sulfonylureas. Caution is also needed in cases of excessive alcohol consumption, prolonged fasting, or impaired liver function.
This drug is primarily excreted through the kidneys, so regular kidney function tests should be conducted, and it should not be administered in cases of impaired kidney function. Elderly patients are also commonly affected by renal impairment and should exercise special caution.
Symptoms of pancreatitis such as acute pancreatitis may occur, so if severe or persistent abdominal pain develops, immediate consultation with a physician is necessary. Additionally, if blisters or rashes appear on the skin, it is advisable to discontinue this medication and seek medical attention from a specialist.
Vitamin B12 levels may decrease, so monitoring blood vitamin B12 concentrations is necessary during long-term use.
This medication should be swallowed whole and not crushed, chewed, or broken, although the tablet shell may appear in the stool, which is normal.
Interactions may occur when taken with other medications, especially those that affect kidney function or other hypoglycemic agents, so consultation with a physician or pharmacist is recommended.
It is better to avoid using this medication during pregnancy or breastfeeding, and if planning to become pregnant, it is important to consult a physician to determine appropriate treatment options.
Safety in children has not been established, so it is not used in pediatric patients.
In case of overdose, gastrointestinal disturbances or lactic acidosis may occur, and immediate hospital treatment is necessary.
When storing, keep out of reach of children, avoid moisture, and do not transfer to another container.
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This helps to preserve the medication's efficacy and safety for a longer period.
Appearance and packaging
Appearance
Oval sustained release tablet, white to nearly white, imprinted with 5LM on one side
Package unit
28 tablets/box (7 tablets/PTP x 4)
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.